Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Quanterix (NASDAQ: QTRX), a biomarker detection company, has granted inducement restricted stock units (RSUs) to 20 new employees who joined through the Akoya Biosciences acquisition. The equity awards, totaling 267,269 RSU shares, were approved on July 8, 2025, under Nasdaq Rule 5635(c)(4).
The RSUs will fully vest after one year from the grant date, contingent on continued employment with Quanterix or its subsidiaries. These grants were made as part of the employees' compensation packages and served as inducements for their employment acceptance.
Quanterix (NASDAQ: QTRX) has completed its acquisition of Akoya Biosciences, creating an integrated platform for biomarker detection across blood and tissue. The transaction involved issuing 7.8 million shares of Quanterix common stock and $20 million in cash to Akoya equity holders.
The merger expands Quanterix's addressable market from $1 billion to $5 billion, focusing on neurology, oncology, and immunology markets. The combined company maintains $163 million in cash post-transaction and targets profitability by 2026. As part of the deal, Scott Mendel and Dr. Myla Lai-Goldman join Quanterix's Board, replacing Martin D. Madaus and Sarah Hlavinka.
Quanterix Corporation (NASDAQ: QTRX), a biomarker detection company, has scheduled its first quarter 2025 financial results announcement for May 12, 2025. The company will release its Q1 2025 results after market close, followed by a conference call at 4:30 p.m. E.T.
Investors can participate in the conference call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 7353673. A live webcast will be available on the News & Events page of Quanterix's website, with the replay accessible for one year.
Kent Lake, holding 7.7% of Quanterix shares, has strongly criticized the company's amended merger agreement with Akoya Biosciences. The key issue is Quanterix's decision to remove shareholders' voting rights on the merger, despite reports showing nearly 3-to-1 opposition to the deal.
The statement highlights concerning financial impacts, noting that Quanterix's stock price has fallen 48% and enterprise value has declined over 100% since the merger announcement. Kent Lake directly challenges CEO Masoud Toloue's claim about the merger's "strong strategic merits."
In response, Kent Lake will continue its push to elect three new board members at the upcoming Annual Meeting, arguing that the current board has proven unable to represent shareholder interests effectively. The investor views this boardroom change as increasingly urgent following what they describe as a "value-destructive transaction" and "shocking disenfranchisement" of shareholders.
Quanterix and Akoya Biosciences have announced amended merger terms, revising their previous agreement. Under the new terms, Quanterix will issue approximately 7.76 million shares and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 in cash and 0.1461 Quanterix shares.
The revised deal structure results in 9 million fewer shares being issued compared to the original terms. Post-merger ownership will be split with Quanterix shareholders holding approximately 84% and Akoya shareholders owning 16% of the combined company.
The amended agreement has received approval from both companies' boards, with over 50% of Akoya shareholders agreeing to vote in favor. The merger is expected to close in Q2 2025, subject to standard closing conditions. Goldman Sachs is advising Quanterix, while Perella Weinberg Partners is serving as Akoya's financial advisor.